

# RAF Proto Oncogene SerineThreonine Protein Kinase - Pipeline Review, H2 2019

<https://marketpublishers.com/r/RC8AE89934DCEN.html>

Date: December 2019

Pages: 65

Price: US\$ 3,500.00 (Single User License)

ID: RC8AE89934DCEN

## Abstracts

RAF Proto Oncogene SerineThreonine Protein Kinase - Pipeline Review, H2 2019

### SUMMARY

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme is encoded by the RAF1 gene. Once activated the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. It plays an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) pipeline Target constitutes close to 19 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology and Musculoskeletal Disorders which include indications Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer, Gastric Cancer, Hepatocellular Carcinoma, Liver Cancer, Solid Tumor, Bladder Cancer, Breast Cancer, Esophageal Cancer, Fibrosis, Gastrointestinal Stromal Tumor (GIST), Kidney Cancer (Renal Cell Cancer), Low-Grade Glioma, Lung Cancer, Metastatic Melanoma and Sarcomas.

The latest report RAF Proto Oncogene Serine/Threonine Protein Kinase - Pipeline Review, H2 2019, outlays comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)

The report reviews RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Overview

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

Apollomics Inc

Basilea Pharmaceutica Ltd

BridgeBio Pharma Inc

Chugai Pharmaceutical Co Ltd

Hanmi Pharmaceuticals Co Ltd

Jazz Pharmaceuticals Plc

Metagone Biotech Inc

Millennium Pharmaceuticals Inc

Novartis AG

Redx Pharma Plc

Samjin Pharm Co Ltd

VG Life Sciences Inc

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Drug Profiles

(MG-005 + sorafenib) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(MG-010 + sorafenib) - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
APL-102 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
BAL-3833 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
belvarafenib - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
CKI-27 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
DCBCI-0902 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
FYA-1001 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
hydroxychloroquine + sorafenib tosylate - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
LXH-254 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
REDX-05358 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress

**SJP-1601 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

Small Molecule to Inhibit FLT, FLT3, FLT4, FMS, c-KIT, LYN, RAF1, RET, PDGFRa and PDGFRb for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&amp;D Progress

Small Molecule to Inhibit Pan-RAF Kinase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&amp;D Progress

Small Molecule to Inhibit RAF1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&amp;D Progress

Small Molecules to Inhibit CRAF and BRAF for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&amp;D Progress

Small Molecules to Inhibit Pan-RAF Kinase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&amp;D Progress

Small Molecules to Inhibit Pan-RAF Kinase Musculoskeletal Disorders and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&amp;D Progress

**TAK-580 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Dormant Products

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Discontinued Products

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or

RAF1 or EC 2.7.11.1) - Product Development Milestones

Featured News & Press Releases

Jun 05, 2019: Belvarafenib confirms efficacy for solid cancer without approved treatment

Apr 01, 2019: Apollomics presents positive preclinical data on APL-102, an oral multi-kinase inhibitor with CSF-1R activity

Apr 17, 2018: BT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of Its Multi-Tyrosine Kinase Inhibitor, CBT-102, at AACR Annual Meeting 2018

May 05, 2017: Hanmi Pharmaceutical Announced IND Approval of HM95573, a Novel Oral RAF inhibitor

Jan 06, 2017: Hanmi presents pan-RAF inhibitor preclinical trial results at Europe Cancer Symposium

Jun 17, 2016: Hanmi presented the clinical trial results of targeted anti-ancer drug HM95573 at ASCO

Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting

Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting

Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent

Nov 10, 2014: Hanmi To Initiate A Phase 1 Clinical Trial Of HM95573, The Next Generation Targeted Therapy For Melanoma Treatment

Sep 04, 2014: VG Life Sciences Progress Update Phase I Cancer Study

Mar 14, 2014: VG Life Sciences's Reports on Clinical Outcomes in Phase I Cancer Study

Dec 13, 2013: VG Life Sciences Update on Phase I Cancer Study

Jul 25, 2013: VG Life Sciences Reports on Scientific Advancements: Completion of Third Cohort of Phase I Clinical Trial; Grant from the American Heart Association;

Apr 04, 2013: VG Life Sciences Reports Positive Safety Results Of Hydroxychloroquine And Sorafenib Combination Therapy In Second Cohort Of Phase I Solid Tumor Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Indication, H2 2019  
Number of Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Number of Products under Investigation by Universities/Institutes, H2 2019  
Products under Investigation by Universities/Institutes, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Pipeline by Apollomics Inc, H2 2019  
Pipeline by Basilea Pharmaceutica Ltd, H2 2019  
Pipeline by BridgeBio Pharma Inc, H2 2019  
Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019  
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2019  
Pipeline by Jazz Pharmaceuticals Plc, H2 2019  
Pipeline by Metagone Biotech Inc, H2 2019  
Pipeline by Millennium Pharmaceuticals Inc, H2 2019  
Pipeline by Novartis AG, H2 2019  
Pipeline by Redx Pharma Plc, H2 2019  
Pipeline by Samjin Pharm Co Ltd, H2 2019  
Pipeline by VG Life Sciences Inc, H2 2019  
Dormant Products, H2 2019  
Dormant Products, H2 2019 (Contd..1), H2 2019  
Discontinued Products, H2 2019



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

Apollomics Inc

Basilea Pharmaceutica Ltd

BridgeBio Pharma Inc

Chugai Pharmaceutical Co Ltd

Hanmi Pharmaceuticals Co Ltd

Jazz Pharmaceuticals Plc

Metagone Biotech Inc

Millennium Pharmaceuticals Inc

Novartis AG

Redx Pharma Plc

Samjin Pharm Co Ltd

VG Life Sciences Inc

## I would like to order

Product name: RAF Proto Oncogene SerineThreonine Protein Kinase - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/RC8AE89934DCEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RC8AE89934DCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970